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Abstract 
Pregnant women and infants are at an increased risk of severe disease after influenza infection. 
Maternal immunisation is a potent tool to protect both of these at-risk groups. Whilst the primary 
aim of maternal influenza vaccination is to protect the mother, a secondary benefit is the transfer of 
protective antibodies to the infant. A recent study using the tetanus, diphtheria and acellular 
pertussis (Tdap) vaccine indicated that children born to mothers immunised in the second trimester 
of pregnancy had the highest antibody titres compared to children immunised in the third trimester. 
The aim of the current study was to investigate how timing of maternal influenza immunisation 
impacts infant antibody levels at birth. Antibody titres were assessed in maternal and cord blood 
samples by both IgG-binding ELISA and haemagglutination inhibition assay (HAI). Antibody titres to 
the H1N1 component were significantly higher in infants born to mothers vaccinated in either the 
second or third trimesters than infants born to unvaccinated mothers. HAI levels in the infant were 
significantly lower when maternal immunisation was performed less than four weeks before birth. 
These studies confirm that immunisation during pregnancy increases the antibody titre in infants. 
Importantly antibody levels in cord blood were significantly higher when mother was vaccinated in 
either trimester two or three, though titres were significantly lower if the mother was immunised 
less than 4 weeks before birth. Based on this data, seasonal influenza vaccination should continue to 
be given in pregnancy as soon as it becomes available. 
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Introduction  
Pregnant women and their infants, especially neonates, are at a higher risk of severe illness caused 
by influenza virus infection 1, 2. During the 2009 H1N1 pandemic, pregnant women were 7.2 times 
more likely to be admitted to hospital due to serious influenza associated disease compared to non-
pregnant women 3. Furthermore, maternal influenza infection has been associated with serious 
complications, such as stillbirth and pre-term delivery 4. Influenza infection is also more severe in 
infancy; for children under 2 years of age, influenza infection is one of the most significant causes of 
hospitalisation, with infants under 6 months of age experiencing the highest rates of morbidity and 
mortality 5,6.  
The influenza vaccine remains the best way to protect high risk populations 7. Multiple randomised 
controlled trials and observational studies have shown that vaccinating pregnant women with 
influenza vaccine is safe throughout pregnancy for both the mother and the neonate 8-10. Maternal 
influenza immunisation is also effective; vaccine-induced antibody protects the mother against 
influenza infection 10. Maternal influenza immunisation has also been probabilistically linked to 
reduced risk of stillbirth 11 confirmed in a meta-analysis 12. Additionally, a study from Bangladesh 
showed that infants born during influenza season to vaccinated mothers were 70% less likely to be 
born premature and 69% less likely to be small for gestational age 4. The published studies support 
immunisation as an effective strategy to protect pregnant women against influenza infection and to 
improve pregnancy outcomes for women and their infants.  
Current influenza vaccines are not licensed for infants younger than 6 months of age, a period of 
high susceptibility for influenza infection. However, we can take advantage of a facet of the immune 
system during pregnancy: maternally derived IgG is actively transported via the placenta from 
mother to foetus, offering passive immunity against infections to infants up to 6 months 13. This 
means that immunising the mother has the potential to protect the infant from influenza infection 
via passive protection with maternal antibody 7, 14. This principle is well established for the 
prevention of neonatal tetanus and also more recently for pertussis 15. Since 2005, immunisation of 
pregnant women with inactivated influenza vaccine has been recommended by the World Health 
Organisation to protect both mothers and their infants. Maternal influenza vaccination significantly 
increases the antibody titre in the infant at birth and up to 2-3 months of age, but reduces the risk of 
infection for up to 6 months of age 16. This vaccine-induced increase in antibody is clinically 
efficacious in protecting infants, with 45-63% reduction in laboratory-confirmed influenza among 
newborns and infants depending on models 10, 17, 18.  
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Whilst it is clear that maternal immunisation is beneficial, recent studies have raised questions about 
the best timing of immunisation for transfer of protection to the infant. Eberhardt et al. suggest that 
antigen-specific cord blood antibody titres were greater following maternal immunisation with the 
tetanus, diphtheria and acellular pertussis (Tdap) vaccine in the second rather than the third 
trimester 19, 20. The results from published studies on timing of maternal influenza vaccination paint 
an incomplete picture. One study observed no difference in antibody levels in cord blood following 
vaccination in different trimesters 16 and another study observed significantly lower antibody titres if 
vaccination was given less than 15 days before birth 21. However, other studies have not observed 
statistically significant differences in post-partum IgG levels in maternal blood 22, 23. It is therefore 
important to further investigate the effect of maternal vaccination timing on anti-influenza antibody 
in their offspring. 
The aim of the current study was to evaluate the effect of timing of inactivated influenza vaccination 
during pregnancy on the antibody level in both the mother and the newborn. This was to improve 
understanding of influenza vaccination pregnancy but also to see if there are general lessons that 
can be learnt with regards the timing of maternal vaccination. 
  
5 
 
Methods 
Recruitment 
The study was an opportunistic study nested within a larger prospective cohort study of maternal 
immunisation (MatImms@Imperial) investigating the effects of maternal pertussis vaccination. 
Samples were collected between November 2013 and October 2016; this period covered four 
different influenza seasons, September to March in the northern hemisphere, and four different 
vaccine composition recommendations (Table S1). Samples from 96 women, 61 vaccinated and 35 
unvaccinated were included in this sub-study out of 383 recruited to the overall MatImms@Imperial 
study. Samples were selected based on availability of material for analysis with an aim to get even 
numbers of participants from each of the three trimesters, aliquots of the samples were used for the 
ELISA and HAI analyses. 26% (n=17) of participants were vaccinated in trimester one (weeks 0-13), 
23% (n=14) in trimester two (weeks 14-26) and 49% (n=30) in trimester three (weeks 27-42) with 
samples selected from the larger study to reflect a range of trimesters of immunisation. The supplier 
of the influenza vaccine was not recorded. Healthy pregnant women were recruited antenatally and 
gestational age was determined by antenatal ultrasound. Healthy, low risk pregnancies with babies 
born at term- above 36 weeks and a birth weight above 2.5 kg were included. Mothers with chronic 
infections known to be transferred to the infant (HIV, hepatitis B and syphilis), chronic conditions 
(e.g. diabetes, autoimmune diseases, high blood pressure) or twin pregnancies were excluded. On 
recruitment, women were asked if they had experienced any illness during their pregnancy. Only 
those who reported no significant illness were recruited. We cannot exclude that some women 
experienced sub-clinical flu during pregnancy. The study was approved by the National Research 
Ethics Service (NRES), NHS, UK (REC 13/LO/1712). Written informed consent was obtained from all 
women and samples were stored under the Imperial College Healthcare Tissue Bank (ICHTB).  
Sampling procedure and laboratory assays  
Blood samples were collected from the mother at or within 2 days of delivery. Umbilical cord blood 
samples were collected at delivery. Blood was collected into Z Serum Sep Clot Activator tubes 
(Greiner Bio-One). All samples were processed in the laboratory within 4 hours and sera were stored 
at -80°C until further analysis. Laboratory staff were blinded to all clinical data. 
Influenza antigen-specific ELISA  
A standardised ELISA assay 24, 25 was used to measure antibodies (IgG) specific to the Influenza 
strains present in the vaccine (A/California/7/2009, A/Texas/50/2012 or B/Massachusetts/2/2012). 
Plates were coated with purified influenza virus antigens (GSK, Sienna) diluted 1µg/ml in PBS. A 
serial dilution of human IgG from serum (Sigma-Aldrich) was used for the standard curve in order to 
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quantify the influenza virus specific IgG in the sample, captured with anti-human Kappa (Southern 
Biotech Cat No 2060-01) and anti-human Lambda (Southern Biotech Cat No 2070-01). The bound IgG 
was detected by HRP-conjugated goat anti-human IgG antibodies (Sigma-Aldrich, Cat No AP112P) 
and the colour change in TMB after H2SO4 stop was read at 450nm.  
Haemagglutination inhibition (HAI) assay  
All samples were analysed by HAI assay using A/California/7/2009 (H1N1) virus strain. Virus was 
grown in Madin-Darby Canine Kidney (MDCK) cells (gift from W. Barclay), in serum-free DMEM 
supplemented with 1µg/ml trypsin. The virus was harvested 3 days after inoculation and stored at -
80°C. Viral titre was determined by haemagglutination assay (HA). Cord and maternal serum samples 
were pre-treated with Receptor Destroying Enzyme (RDE: Denka Seiken) for 18 hours at 37°C before 
inactivating the enzyme at 56°C for one hour. All treated sera were tested for non-specific 
agglutination before analysing with HAI assay. RDE-treated serum was two-fold serially diluted 
across the plate with PBS and incubated with pre-diluted 4 haemagglutinating unit virus per well for 
15 minutes at room temperature. 100µl of 0.5% turkey erythrocytes diluted in PBS was then added 
to each well, and the plate was incubated for 30 minutes at room temperature before scoring the 
response. Seroprotection was defined as an HAI titre ≥40 based on challenge studies 26. 
Statistical analysis 
Descriptive statistics were carried out to investigate any differences in baseline characteristics 
between the vaccinated and un-vaccinated groups using the Student’s t-test. For comparisons of 
trimester on antibody titre, ANOVA followed by Bonferroni’s multiple comparison test was used to 
account for multiple comparisons; specific pairwise comparisons are described in figure legends. 
Fisher’s exact test was used compare proportions of seroprotection. 
Univariate analyses were conducted to assess associations of mean H1N1 maternal and cord 
antibody titres with a range of socio-demographic and clinical risk-factor variables. Crude 
associations between vaccination status, trimester of vaccination, and other variables, with mean 
antibody titres were obtained using two sided Student’s t-test; datasets were tested for normality 
using the D'Agostino & Pearson test.  
Variables that showed evidence of association with mean antibody titres at the p≤0.1 level in the 
univariate analysis, were analysed further in multivariable analyses using logistic regression models. 
In multivariable analyses the relationship between vaccination status; trimester of vaccination; and 
season of birth; and H1N1 cord blood titre were quantified using a logistic regression model. The 
outcome was defined as the upper 50th centile of H1N1 antibody titre in cord blood. All tests were 
performed using GraphPad Prism 7.02 (GraphPad, USA). Transfer ratios were calculated as the 
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maternal titre divided by the cord blood titre. Post hoc power analysis was performed with Gpower 
27. 
Data availability statement 
The complete raw dataset is available in supplementary data file (File S1).  
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Result 
Study population  
63.5% (n=61) of the study population had received seasonal influenza vaccine during pregnancy, 
35% (n=35) were unvaccinated (Table 1). There were no significant differences in age, BMI, ethnicity 
or parity between vaccinated and unvaccinated pregnant women. Of the vaccinated mothers, 5% of 
study population received the vaccine in the 2013-14 influenza season, 62% in the 2014-15 season, 
31% in the 2015-16 season and 2% in the 2016-2017 season: it is of note that the same H1N1 
antigen was used in all of the seasons included in the study (Table S1). For the newborns, there were 
no significant differences in terms of gestational week, birth weight or sex between those born to 
vaccinated mother compared to newborns with unvaccinated mother. When infants were grouped 
by maternal vaccination trimester, there were no significant differences in terms of gestational age, 
birth weight or sex ratio (Table 2). All infants included in the study were delivered at term (mean 
gestational age 39.9 weeks) and no infants were categorised as low birth weight (defined as less 
than 2.9kg for male children or 2.8kg for female children at 40 weeks).  
Vaccination in the second and third trimesters significantly elevates H1N1 specific IgG at birth in 
mothers and newborns 
ELISA was used to quantify the influenza specific IgG titre in cord and maternal serum samples 
collected at the time of birth. H1N1 specific IgG titres were significantly higher in the cord blood of 
babies born to vaccinated rather than unvaccinated mothers (P=0.016, Figure 1A). The cord samples 
had significantly higher antibody titres than the maternal samples (P=0.031). The transfer ratio for 
H1N1 in matched vaccinated pairs (3.199 ± 3.203) was significantly greater (P=0.0023) than in 
unvaccinated pairs (1.397 ± 0.9174). There was no significant difference in anti-H1N1 binding 
antibodies measured by ELISA between vaccinated and unvaccinated mothers. 
Analysis of antibody titres on cord blood samples was carried out in relation to the stage of 
pregnancy at the time of immunisation compared to the unvaccinated group (Table 2); mothers and 
their infants were grouped based on whether they were vaccinated in the first (n=17), second (n=15) 
or third trimester (n=29). Cord blood samples from infants born to mothers vaccinated in the second 
(P=0.0336) or third (P=0.0084) trimester had significantly higher H1N1 specific IgG titre at birth 
compared to infants from unvaccinated mothers (Figure 1B). There was no significant difference in 
the antibody titre in babies born to mothers vaccinated in the first trimester compared to those born 
to non-vaccinated mothers. In the maternal samples, H1N1 specific IgG responses in mothers 
vaccinated in the second trimester were significantly higher than in unvaccinated mothers 
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(P=0.0036, Figure 1C). The transfer ratio for H1N1 specific antibody in matched vaccinated pairs was 
significantly different between T1 (3.61 ± 2.289, P=0.024), and T3 (3.15± 3.758, P=0.0337) and 
unvaccinated pairs (1.397 ± 0.9174), but not T2 (2.819± 3.042). 
Vaccination in the second and third trimesters significantly elevates HAI at birth in mothers and 
newborns 
To further dissect the level of protection provided by maternal vaccination, we measured the degree 
of haemagglutination inhibition (HAI) in the samples. The HAI titre that is currently used as a 
correlate of influenza protection was defined in the 1970’s in a series of human influenza challenge 
studies 26. Since the H1N1 vaccine strain was unchanged through the course of the study, we 
focussed the HAI on a representative H1N1 virus (A/California/7/2009). The HAI titre in cord blood of 
babies born to vaccinated mothers was significantly higher than in infants born to unvaccinated 
mothers (Figure 1D). The HAI titre was also higher in cord blood from vaccinated mothers than in the 
maternal blood. The HAI titre in cord blood of babies born to mothers vaccinated in the second 
(P=0.0006) or third (P=0.0006) trimesters of pregnancy was significantly greater than those born to 
unvaccinated mothers (Figure 1E). The maternal HAI titre at the time of birth of mother immunised 
in T3 was significantly higher than unvaccinated mothers (P=0.0294, Figure 1F). The level of antibody 
measured by HAI or ELISA correlated significantly in both the cord (R2=0.3277, P<0.0001, Fig S1A) 
and maternal (R2=0.1697, P= 0.0003, Fig S1B) samples. 
We evaluated the seroprotection rate (proportion of individuals with HAI titre ≥ 40): in infants born 
to vaccinated mothers, the rate was 47%, which was significantly higher than in infants born to 
unvaccinated mothers (Figure 1E, 0%, P<0.001). Likewise, significantly more vaccinated mothers 
(18%) had an HAI titre ≥ 40 compared to unvaccinated mothers (Figure 1F, 0%, P=0.0063). 
Comparing the proportion by trimester, there was a significantly greater proportion (P<0.001) of 
cord blood samples with HAI ≥ 40, if the mothers were immunised in either T1, T2 or T3 than in 
samples from unvaccinated mothers. Likewise the proportion of mothers with HAI ≥ 40 were 
significantly greater than unvaccinated mothers if they were immunised in T1 (P=0.01), T2 
(P=0.0047) or T3 (P=0.041). 
Immunisation between 24 weeks gestation and 5 weeks before birth led to the highest antibody 
titre in the cord samples 
An alternative consideration to assess the protective potential of a vaccine given in pregnancy is the 
interval between immunisation and delivery, which can inform us about the kinetics of antibody 
transfer. In particular we wanted to compare the effect of immunisation very close to the time of 
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birth (less than 4 weeks) to see whether this affected transfer. When grouped this way, infants from 
mothers vaccinated either 5-12 (P=0.0237) or 13-24 weeks (P=0.0107) before delivery had 
significantly higher H1N1 specific IgG titre at birth compared to those from unvaccinated mothers 
(Figure 2A). There was no significant difference between infants whose mother received vaccination 
either less than 4 weeks or more than 24 weeks before birth and infants born to unvaccinated 
mothers. Mothers vaccinated 13-24 weeks before delivery had the highest IgG response at time of 
delivery among all vaccination groups, and the titre was significantly higher than unvaccinated 
mothers (P=0.0177, Figure 2B). HAI titres were also compared by interval to delivery. Newborns 
from mothers vaccinated 5-12 weeks before delivery had the highest HAI titre (Figure 2C) and were 
significantly greater than titres in newborns vaccinated less than 4 weeks, newborns from mothers 
vaccinated either 5-12 or 13-24 weeks before birth had significantly higher HAI titres than those 
from unvaccinated mothers. Maternal HAI titres at birth were not significantly different regardless of 
the interval between vaccination and birth (Figure 2D). In terms of seroprotection, administration of 
maternal influenza vaccine 5-12 weeks before delivery conferred the highest percentage of infants 
with HAI titre ≥ 40 (58.8%). All timings had a significantly greater proportion of infants with HAI titre 
≥ 40 than the unvaccinated group.. These data suggest that immunising too close to the time of birth 
reduces the amount of antibody transferred to the infant. 
Season of birth 
Due to the seasonality of influenza, we determined if season of birth affected antibody titres. There 
was no difference in the season of birth between vaccinated and unvaccinated groups (Table 1). The 
anti-H1 IgG titre was significantly greater at birth in unvaccinated infants born in the influenza 
season (P=0.043, Figure 3A) but not children born to vaccinated mothers (Figure 3B). We then 
investigated the relationship between month of birth and antibody titre. In children from 
unvaccinated mothers, there was a weak but significant decline in antibody titre (P=0.02, R2=0.16, 
Figure 3C) from those born at the start of the influenza season (September) to those born before the 
beginning of the next season (August). This relationship was not seen in the vaccinated group 
(P>0.05, R2=0.07, Figure 3D). Since season had an effect on antibody titre we compared month of 
birth with trimester of vaccination. The majority of mothers were immunised in October, regardless 
of trimester (Figure 3E). This was subsequently reflected in a significant difference in the median 
month of birth (Table 2), with children born to mothers immunised in trimester 3 born earlier in the 
influenza season, than children born to mothers immunised in trimester 1 (Figure 3F). 
Impact of timing of maternal vaccination to H3N2 and B components of trivalent influenza vaccine 
11 
 
The influenza vaccine that is routinely used in pregnancy covers three different strains of influenza, 
normally two influenza A strains and one influenza B strain (Table S1). This gave us the opportunity 
to investigate whether there were similar effects to co-administered antigens. Analysis was 
restricted to the 13-14 and 14-15 influenza seasons as the same vaccine composition was used in 
these two seasons, enabling comparison to the same antigens; this did reduce the number of 
subjects studied (unvaccinated n=34, vaccinated n=41, T1 n=13, T2 n=9, T3 n=19). Antibody levels to 
the H3N2 antigen (A/Texas/50/2011) were compared between vaccinated and unvaccinated 
mothers and their infants; there was no significant difference observed between groups (Figure 4A). 
No difference was seen when cord (Figure 4B) or maternal (Figure 4C) samples were grouped by 
trimester, though there was a trend to increased titre in mothers vaccinated at T3 (T3 titre 296.6 ± 
382.6, unvaccinated titre 147.2 ± 170.5, adjusted P=0.1483). The H3N2 specific antibody transfer 
rate was not significantly different between groups. 
We also measured antibody titres to the influenza B component (B/Massachusetts/2/2012). There 
was no difference in influenza B specific antibody titre between vaccinated or unvaccinated 
maternal samples or cord from maternal samples (Figure 4D), though the mean titre in the 
vaccinated group (482 ± 600) was higher than the mean titre in the unvaccinated group (323 ± 387). 
There was a trend towards higher antibody titres in the T3 groups in both cord (Figure 4E) and 
maternal (4F) samples, but this was not significant. In the unvaccinated samples birth timing relative 
to influenza season had no effect on the H3N2 titre (Figure 4G), but there was a significant 
difference in the cord sample in children born in influenza season (P=0.036, Figure 4H). 
Determinants of influenza specific antibody titre in cord and maternal blood samples  
Having observed that a number of factors contributed to antibody levels in pregnant women and 
their infants at birth, we used univariate analysis to determine their relative contributions. 
Vaccination status significantly impacted cord IgG (Table 3) and HAI titres (Table S2); it also had a 
significant impact on maternal HAI titre (Table S2). Vaccination trimester and birth season also had a 
significant impact on cord and maternal antibody titres. Parity, maternal age, maternal BMI, 
ethnicity and mode of delivery did not significantly impact vaccine-specific antibody levels in infants. 
Interestingly mothers with BMI≥25 had significantly lower H1N1 titres (P=0.04) than mothers with 
BMI<25, and mothers who gave birth after 40 weeks also had significantly lower IgG titres 
(P=0.0047), though this difference was not seen in the HAI titre. 
For multivariable analyses the upper 50th percentile of H1N1 IgG cord blood concentration was used, 
which ranged from 194.0 – 1205.6 µg/ml (Table 4). It should be noted that due to sample size 
limitations a broad outcome group (upper 50th percentile H1N1 IgG titre: which represents mothers 
12 
 
with H1N1 antibody titres above the mean of this study population) was used for multivariable 
analysis, which is important to consider when interpreting these results. 74.1% of cord blood 
samples with a protective HAI titre >40 fell within this group. Vaccinated mother-infant pairs were 
3.7 (1.5-9.3) times more likely to be in the upper half of H1N1 IgG concentration relative to 
unvaccinated pairs, controlling for season of birth. Mother-infant pairs vaccinated in T1, T2 and T3 
were 3.4, 8.1 and 2.5 times more likely to be in the upper H1N1 cord blood concentration group 
respectively, compared to unvaccinated pairs, after adjustment for season of birth; this was 
significant only for T2 (P= 0.005). Mother-infant pairs that gave birth/were born in the flu season had 
significantly increased odds of 3.1 (1.1-9.3) of being in the upper H1N1 IgG cord concentration 
group, relative to those born in the non-flu season, after controlling for vaccination status and 
trimester of vaccination.  
 
Discussion 
The aim of the study was to assess the effect of timing of influenza vaccination during pregnancy on 
the antibody levels in both infants and mothers. Vaccination significantly increased the antibody 
titre at the time of birth in both the mother and the infant. It should be noted that unvaccinated 
mothers still pass influenza specific antibodies to their children, more so in the influenza season 
probably reflecting natural infection or exposure to virus in the mothers. Infants from mothers that 
received influenza vaccine at 5-24 weeks before delivery (second trimester to mid third trimester) 
had significantly higher HAI and specific IgG titres against influenza A (H1N1) than infants from 
unvaccinated mothers. If their mother was immunised either too far from (>24 weeks) or very close 
to (<4 weeks) delivery, the antibody titre in the infant was no different to infants from unimmunised 
mothers. Similar results were reported in a previous study, with significantly increased HAI antibody 
titre in the cord blood of infants born to mothers vaccinated more than 30 days before delivery 21. 
We also observed an association between birth season and antibody titre, but only in children born 
to unvaccinated mothers. 
Previous studies have shown that maternal immune responses to the influenza vaccine are 
independent of the trimester 22, 23. Therefore differences in antibody titres seen in newborns after 
immunisation at the second or third trimester during pregnancy are presumably the result of 
cumulative antibody transfer across the placenta. Placental transfer of IgG antibody is facilitated by 
the neonatal Fc receptor (FcRn), with transport efficiency increasing over time 28, and is believed to 
be maximal in the third trimester. Immunising mid-pregnancy gives enough time for the mother to 
develop high antibody levels while allowing time for maternal-fetal antibody transfer. Immunisation 
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at the end stages of pregnancy (less than 4 weeks before delivery) is unlikely to allow sufficient time 
for the mother to both respond to the vaccine and transfer antibody to the foetus. It is not fully clear 
why the antibody titre at birth is not significantly greater in mothers vaccinated during T1 compared 
to unvaccinated mothers. But one consideration is that the comparison is not against an immune 
naïve population, both vaccinated and unvaccinated mothers will have been exposed to influenza 
antigens and therefore vaccination is boosting from a baseline, which may wane over time. Since 
there is minimal antibody transfer in the first trimester29, by the time of peak antibody transfer later 
in pregnancy, the titre in the serum of T1 vaccinated mothers may not be different to unvaccinated 
mothers, especially if the unvaccinated mothers are exposed to influenza during pregnancy.  
It was of note that antibody levels in cord blood samples were higher than in maternal blood 
samples. A similar pattern has been observed after immunisation of pregnant women with 
inactivated monovalent H1N1 30, pertussis and pneumococcus 31-33 vaccines. This could be a result of 
either the active transfer of antibody across the placenta or the increased circulating volume in 
pregnant women at the time of birth which decreases IgG antibody concentration in proportion as 
pregnancy proceeds 34. We also observed lower antibody titres in mothers with children born at 
greater gestational ages, suggesting that increasing serum dilution in the mother over the course of 
pregnancy might be more important in this difference between the infant and the maternal titres. 
Another intriguing association was between maternal BMI and antibody titre by ELISA; why this is 
the case is not clear; there was a discrepancy between the association between titre, HAI and BMI, 
which is likely caused by the small sample size.  
There are two important considerations relating to maternal influenza vaccination when considering 
optimal timing. Firstly the vaccine for influenza, unlike other pathogens, changes annually to reflect 
changes in the circulating strains of virus, which restricts the availability of the vaccine to certain 
times of the year. The current practice is to immunise mothers as soon as the influenza vaccine 
becomes available (late September, early October) giving them the greatest protection throughout 
the influenza season, and in our study the majority of individuals were vaccinated in October, at the 
start of the flu season in the UK. Secondly, the goal of maternal influenza immunisation is to protect 
both the mother from infection throughout pregnancy and the infant during the first months of life; 
this is different to experimental Group B streptococcus (GBS) and respiratory syncytial virus (RSV) 
vaccines where the priority is to protect the infant; though the ongoing Novavax trial is also looking 
at the effect on maternal RSV infection (NCT02624947), which may provide additional cocooning 
benefit to the child. Since the aim of maternal influenza immunisation is to protect both mother and 
child, there is a potential trade-off in the optimal timing between vaccinating early to provide 
protection to the mother for the course of the pregnancy and vaccinating later to maximise transfer 
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and longevity of antibody to the child. However the seasonality of infection and the increased 
antibody level in children born to mothers immunised later in pregnancy mean that vaccinating early 
in the influenza season achieves the twin goals of protecting both the mother and the child. This is 
because vaccinated mothers who give birth during the influenza season will mostly be in the later 
stages of their pregnancy at the time of immunisation and therefore their babies will have more 
anti-influenza antibody at the time of birth, whereas mothers who are early in pregnancy at the time 
of vaccination are less likely to give birth during the influenza season, therefore protecting the 
mother for the course of the pregnancy is the main target of vaccination. This interaction of season 
and response may only apply in areas with short and reliable influenza seasons. One other 
consideration is that maternal immunisation later in pregnancy may have a cocooning effect: 
prevention of maternal infection will reduce transmission from the mother to her infant. 
This was a smaller opportunistic study nested within a larger study, the original study was not 
designed to answer the question about timing of influenza vaccination in pregnancy and the analysis 
was applied retrospectively to samples collected. As such there are a number of limitations. The 
donor numbers are small and not evenly spread across the three trimesters so we did not have 
sufficient power to determine whether there were significant differences between trimesters. While 
the data suggests an equivalence between T2 and T3 in the anti-H1 titre, a post-hoc power 
calculation using the data obtained in the Gpower package 27 gives a low power (0.05), which is a 
95% chance of a type II error, i.e. a failure to reject the null hypothesis that T2 and T3 are the same. 
Performing the same analysis to compare T1 and T3 gave a power of 60%. Therefore analysis 
focused on comparison of the trimesters against the unvaccinated groups, for which the study was 
adequately powered (power=98% using Gpower). The data presented here can be used to inform 
power calculations for future studies: to detect a difference between T1 and T2 would have required 
42 individuals per arm and T1 and T3 would have needed 56 individuals per arm and for a difference 
between T2 and T3 14,355 individuals per arm. This problem of small group sizes is exacerbated in 
the H3N2 and B datasets which are taken from fewer seasons to look at equivalent antigens. We do 
not know the previous influenza vaccination or infection status of the donors and the seasonality 
data suggests that infection is a confounding effect. We focussed on IgG ELISA and HAI assays, but 
other assays to measure antibody function, for example neutralisation assays would also be 
informative. There was a significant effect of birth season in the unvaccinated mothers, which is 
most likely driven by natural infection. Ultimately, the study shows that maternal vaccination 
increases infant anti-influenza titre and given the seasonality of influenza infection, our study 
supports the administration of influenza vaccine as soon as it becomes available. 
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Maternal immunisation is one of the safest and most useful tools to address the limited immunity of 
infants during first months of life, aiming to close the gap in infant protection until it is possible to 
immunise the infant 14. The administration of influenza and Tdap vaccines during pregnancy have 
shown to be clinically efficacious in protecting infants from infections 7. Developing maternal 
vaccination for other major pathogens that cause infections in early life, including RSV 35 and GBS 36 
is a research priority. The timing of vaccine administration is critical in optimising the windows of 
protection. Studies in maternal immunisation against pertussis suggest that trimester two is the 
optimum time for maternal immunisation to maximise protection in the infant 19, 21. In the current 
study we observed that immunisation in trimester two or three, both lead to significantly higher 
titres than in children born to unvaccinated mothers. This suggests that immunisation timing relative 
to pregnancy may be less important for influenza than pertussis and given the seasonal nature of 
influenza infection immunising as soon as the vaccine becomes available is the best approach. 
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Tables 
Table 1. Characteristics of the Study Populations 
Characteristic  Vaccinated  
(n=61) 
Unvaccinated 
(n=35) 
P Value 
Women    
Age, mean (SD) 32.3 (5.1) 32.3 (4.5) 0.995 
BMI, mean (SD) 25.0 (4.4) 24.6 (4.2) 0.7 
Parity, mean (SD) 0.56 (0.8) 0.9 (1) 0.061 
Ethnicity n (% Caucasian) 38 (62.3) 20 (58.8) 0.74 
Newborns    
Gestational age, weeks (SD) 40.0 (1.3) 39.9 (1.1) 0.76 
Mean birth weight, g (SD) 3.5 (0.43) 3.5 (0.4) 0.98 
Female sex, n (%)  27 (44%) 16 (46%) 0.89 
Mode of delivery: Vaginal delivery, n (%)  34 (56%) 23 (65%) 0.13 
Season of birth     
Month of birth (Median) June July 0.23 
Born in flu season (Sept-Mar), n (%) 33 (54%) 18 (51%) 0.8 
P Value for Age, BMI, Parity, Gestational Age, Birth weight, month of birth by t-test; 
P Value for Ethnicity, female sex, vaginal delivery and birth in flu season by Chi-Square test. 
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Table 2. Characteristics of vaccinated pregnant women in the study by the stage of pregnancy at immunisation  
Characteristics  Maternal flu 
immunisation in 
First trimester (n=17) 
Maternal flu 
immunisation in  
Second trimester (n=14) 
Maternal flu 
immunisation in 
Third trimester (n=30) 
P value 
Mothers     
Age, year, mean (SD) 31.7 (4.7) 30.9 (6.0) 33.3 (4.8) 0.28 
Parity, mean (SD) 0.53 (0.8) 0.5 (0.9) 0.6 (0.9) 0.99 
Influenza season at immunisation (%)     
2013-2014 1 (6%) 1 (7%) 1 (3%)  
2014-2015 12 (70%) 8 (57%) 18 (60%)  
2015-2016 4 (24%) 5 (36%) 10 (34%)  
2016-2017   1 (3%)  
Newborns     
Gestational age, weeks (SD) 40.2 (0.9) 40.2 (1.2) 39.7 (1.5) 0.3 
Season of birth:     
 Birth month (median) June April December <0.0001 
 Born in flu season, n (%) 2 (12%) 4 (29%) 25 (83%) <0.0001 
 Month of vaccination (median) October October October 0.9 
Mean birth weight, g (SD) 3.5 (0.4) 3.5 (0.5) 3.5 (0.5) 0.9 
Female sex 9 (53%) 6 (57%) 12 36%) 0.7 
Mode of delivery: Vaginal delivery, n (%)  11 (65%) 9 (64%) 14 (47%) 0.38 
P Value by ANOVA and bonferroni post test. 
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Table 3. Univariate analysis of factors determining the H1N1 antibody titre 
rate in cord and maternal blood samples  
 
 H1N1 Cord Titre  H1N1 Maternal Titre 
N Mean (95%CI) P value N Mean (95%CI) P value 
Vaccination 
Status 
Vaccinated 61 
349.3 (271-
426) 
0.0073 
61 
221.7 (151.8-
291.5) 
0.062 
Un-vaccinated 35 
191.7 (117.78-
265.7) 
35 
133.3 (92.3-
174.2) 
Season of 
Birth 
April-Aug 45 
223.1 (145.0-
301.3) 
0.026 
41 
133.7 (70.0-
197.4) 
0.029 
Sept-Mar  51 
351.2 (268.9-
433.5) 
47 
234.5 (169.7-
299.2) 
Trimester of 
vaccination 
Un-vaccinated 35 
188.3 (113.9-
262.7) 
- 35 
135.5 (93.5-
177.5) 
- 
Trim 1 17 
227.7 (120.3-
335) 
0.547 17 
86.8 (34.5-
139.1) 
0.168 
Trim 2 15 
403.8 (234.8-
572.8) 
0.0069 15 
357.8 (156.9-
558.7) 
0.0015 
Trim 3 29 
392.2 (264.3-
520.1) 
0.0041 29 
225.1 (128.9-
321.2) 
0.067 
Parity 
Primiparous 53 
266.7 (188.2-
345.2) 
0.398 
53 
152.5 (93.5-
211.6) 
0.098 
Multiparous 43 
316.2 (229.3-
403.1) 
43 
229.5 (156.7-
302.3) 
Mother’s age 
20-34 63 
296.8 (223.0-
370.6) 
0.704 
63 
117.3 (122.7-
231.9) 
0.552 
35-42 33 
273.7 (178.3-
369.1) 
33 
206.3 (119.0-
293.6) 
Ethnicity 
**** 
Caucasian 58 
299.5 (221.6-
377.4) 
0.739 
58 
194.6 (129-
259.3) 
0.77 
Other 37 
279.5 (190.8-
368.3) 
37 
180.5 (113.8-
247.1) 
Mode of 
Delivery ** 
Vaginal  45 
322.2 (243.9-
400.5) 
0.323 
45 
236 (161.2-
310.8) 
0.063 
C-Section 49 
264.2 (176.2-
352.1) 
49 
148.2 (90-
206.5) 
Gestation 
35-39 weeks 35 
323.3 (230.4-
416.3) 
0.35 
35 
270.6 (176.5-
364.7) 
0.0047 
≥40 weeks 61 
267.8 (193.3-
342.4) 
61 
137.7 (93.0-
182.3) 
Maternal 
BMI *** 
<25 52 
294.7 (219.8-
369.5) 
0.83 
52 
227.6 (161.3-
294) 
0.04 
≥25 41 
268.1 (175-
350) 
41 
131.9 (70.3-
193.4) 
*P values are results of paired sample t-test relative to the un-vaccinated group. ** Delivery mode 
not recorded for 2 donors. *** BMI not recorded for 3 donors. **** Ethnicity not recorded for 1 
donor. 
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Table 4. Crude and adjusted odds ratios for being in the upper 50th percentile of H1N1 IgG cord 
blood concentration. 
 
+ The vaccination status adjusted OR was controlled for the effect of birth season. 
*The trimester adjusted OR was controlled for the effect of birth season. 
x The birth season adjusted OR was controlled for the effect of vaccination status and trimester of 
vaccination. 
  
  Odds Ratio (95%CI) P Value 
Adjusted Odds 
Ratio (95%CI) 
P Value 
Vaccination 
status+ 
Unvaccinated 1 - 1 - 
Vaccinated 3.6 (1.5-8.9) 0.005 3.7 (1.5-9.3) 0.006 
Trimester of 
vaccination* 
Unvaccinated 1 - 1 - 
Trimester 1 2.2 (0.6-7.8) 0.228 3.4 (0.9-13.9) 0.084 
Trimester 2 5.9 (1.6-23.1) 0.009 8.1 (1.9-34.3) 0.005 
Trimester 3 3.6 (1.2-10.8) 0.020 2.5 (0.8-8.0) 0.120 
Birth Season x 
April-August 1 - 1 - 
September-March 2.29 (0.9-5.4) 0.057 3.1 (1.1-9.3) 0.046 
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Figure 1. Effect of maternal immunisation on maternal and cord ELISA titres. Blood was collected 
from mothers and cord at the time of delivery. Donors were grouped by vaccination status of the 
mother. Antibody titre to H1N1 influenza by ELISA in all individuals (A), or in cord (B) and maternal 
samples (C) by stage of pregnancy at immunisation. HAI titres to H1N1 influenza (D), the dotted line 
represents the level of seroprotection (HAI titre ≥1:40), numbers above are proportion of individuals 
that sero-converted. HAI titres by stage of pregnancy at immunisation in cord (E) and maternal 
samples (F). One way ANOVA and Bonferroni's test : A, D comparison between all groups: B, C, E, F 
comparisons against unvaccinated group. Line represents mean,* P<0.05, **P≤0.01, *** P≤0.001. 
Figure 2. The effect of time interval between maternal vaccination and delivery on anti-influenza 
titres. Individuals were grouped by the time interval between vaccination and delivery. H1N1 
specific IgG titres were measured by ELISA in cord (A) and maternal serum (B). H1N1 specific HAI 
titre was measured by HAI assay in cord (C) and maternal (D) serum samples. The dotted line 
represents the level of seroprotection (HAI titre ≥1:40). One way ANOVA and Bonferroni's test, 
comparisons between all groups and the unvaccinated and 0-4 groups. Line represents mean,* 
P<0.05, **P≤0.01, *** P≤0.001. 
Figure 3: Effect of season of birth and immunisation on antibody titre in mother and cord. 
Maternal and cord samples were grouped by the season of birth comparing those in flu season (born 
Sept-March) to those outside it (Apr-Aug). Antibody titres were compared by birth season in 
unvaccinated (A) and unvaccinated donors (B). Titres in unvaccinated (C) and vaccinated (D) groups 
were compared against month of birth, ordered from the start of the influenza season (Sept). Month 
of vaccination (E) and month of birth (F) for children born to mothers vaccinated in different 
trimesters. One way ANOVA and Bonferroni's test : A, B pairwise comparison between cord and 
maternal groups, line represents mean,* P<0.05, **P≤0.01, *** P≤0.001. 
Figure 4. Effect of maternal immunisation on maternal and cord ELISA titres to H3N2 and B 
antigens. Blood was collected from mothers and cord at the time of delivery. Donors were grouped 
by vaccination status of the mother. Antibody titre to H1N1 influenza by ELISA in all individuals (A), 
or in cord (B) and maternal samples (C) by stage of pregnancy at immunisation. Antibody titre to B 
influenza by ELISA in all individuals (D), or in cord (E) and maternal samples (F) by stage of pregnancy 
at immunisation. Maternal (∆) and cord (●) samples were grouped by the season of birth comparing 
titres to H3N2 (G) or influenza B (H) in flu season (born Sept-March, closed symbols) to those outside 
it (Apr-Aug, open symbols). One way ANOVA and Bonferroni's test : A, D comparison between all 
groups; B, C, E, F comparisons against unvaccinated group; G, H pairwise comparison between cord 
and maternal groups. Line represents mean,* P<0.05.  
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Figure S1. Correlation between HAI and ELISA. Antibody titres measured by different approaches 
were correlated in cord blood samples (A) and maternal blood samples at the time of birth (B). 
 
Figure 1. Effect of maternal immunisation on maternal and cord ELISA titres. Blood was 
collected from mothers and cord at the time of delivery. Donors were grouped by 
vaccination status of the mother. Antibody titre to H1N1 influenza by ELISA in all individuals 
(A), or in cord (B) and maternal samples (C) by stage of pregnancy at immunisation. HAI 
titres to H1N1 influenza (D), the dotted line represents the level of seroprotection (HAI titre 
≥1:40), numbers above are proportion of individuals that sero-converted. HAI titres by stage 
of pregnancy at immunisation in cord (E) and maternal samples (F). One way ANOVA and 
Bonferroni's test : A, D comparison between all groups: B, C, E, F comparisons against 
unvaccinated group. Line represents mean,* p<0.05, **p≤0.01, *** p≤0.001.  
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Figure 2. The effect of time interval between maternal vaccination and delivery on 
anti-influenza titres. Individuals were grouped by the time interval between 
vaccination and delivery. H1N1 specific IgG titres were measured by ELISA in cord 
(A) and maternal serum (B). H1N1 specific HAI titre was measured by HAI assay in 
cord (C) and maternal (D) serum samples. The dotted line represents the level of 
seroprotection (HAI titre ≥1:40). One way ANOVA and Bonferroni's test, 
comparisons between all groups and the unvaccinated and 0-4 groups. Line 
represents mean,* p<0.05, **p≤0.01, *** p≤0.001.  
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Figure 3: Effect of season of birth and immunisation on antibody response in 
mother and cord. Maternal (∆) and cord (●) samples were grouped by the season 
of birth comparing those in flu season (born Sept-March, closed symbols) to those 
outside it (Apr-Aug, open symbols). Antibody titres were compared by birth 
season in unvaccinated (A) and unvaccinated donors (B). Antibody titres in 
unvaccinated (C) and vaccinated (D) groups were compared against month of 
birth, ordered from the start of the influenza season (Sept). Month of vaccination 
(E) and month of birth (F) for children born to mothers vaccinated in different 
trimesters. One way ANOVA and Bonferroni's test : A, B pairwise comparison 
between cord and maternal groups, line represents mean,* p<0.05, **p≤0.01, *** 
p≤0.001. 
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Figure 4. Effect of maternal immunisation on maternal and cord ELISA titres to H3N2 and 
B antigens. Blood was collected from mothers and cord at the time of delivery. Donors were 
grouped by vaccination status of the mother. Antibody titre to H1N1 influenza by ELISA in all 
individuals (A), or in cord (B) and maternal samples (C) by stage of pregnancy at 
immunisation. Antibody titre to B influenza by ELISA in all individuals (D), or in cord (E) and 
maternal samples (F) by stage of pregnancy at immunisation. Maternal (∆) and cord (●) 
samples were grouped by the season of birth comparing titres to H3N2 (G) or influenza B 
(H) in flu season (born Sept-March, closed symbols) to those outside it (Apr-Aug, open 
symbols). One way ANOVA and Bonferroni's test : A, D comparison between all groups; B, C, 
E, F comparisons against unvaccinated group; G, H pairwise comparison between cord and 
maternal groups. Line represents mean,* p<0.05. 
Figure S1. Correlation between HAI and ELISA. Antibody responses measured by different 
approaches were correlated in cord blood samples (A) and maternal blood samples at the time of 
birth (B). 
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Table S1. Seasonal influenza virus vaccine composition (2013-2016) 
Flu season  Influenza virus vaccines composition  
2013 – 2014 - A/California/7/2009 (H1N1) pdm09-like virus  
- A/Texas/50/2012 (H3N2)-like virus  
- B/Massachusetts/2/2012-like virus 
2014 – 2015 - A/California/7/2009 (H1N1) pdm09-like virus  
- A/Texas/50/2012 (H3N2)-like virus  
- B/Massachusetts/2/2012-like virus 
2015 – 2016 - A/California/7/2009 (H1N1) pdm09-like virus  
- A/Switzerland/9715293/2013 (H3N2)-like virus 
- B/Phuket/3073/2013-like virus  
2016 – 2017 - A/California/7/2009 (H1N1) pdm09-like virus 
- A/Hong Kong/4801/2014 (H3N2)-like virus 
- B/Brisbane/60/2008 (Vic)-like virus 
 
  
Table S2. Univariate analysis of factors determining the HAI titre in cord and 
maternal blood samples 
 
 HAI Cord Titre  HAI Maternal Titre 
N Mean (95%CI) p value N Mean (95%CI) p value 
Vaccination 
Status 
Vaccinated 61 48.7 (37.8-59.6) 
<0.0001 
61 19.4 (13.9-24.8) 
0.016 
Un-vaccinated 35 13.1 (8.4-17.8) 35 9.4 (6.5-12.4) 
Season of 
Birth 
April-Aug 45 31.8 (21.6-41.9) 
0.17 
45 12.2 (7.4-17.1) 
0.074 
Sept-Mar  51 43.6 (30.1-57.1) 51 19.2 (13.4-25.1) 
Trimester 
of 
vaccination 
Un-vaccinated 35 13.1 (8.41-17.8) - 35 9.4 (6.5-12.4) - 
Trim 1 17 35.7 (22.9-48.6) 0.0003 17 13 (5.4-20.6) 0.3 
Trim 2 15 60 (30.3-89.7) <0.0001 15 23 (8.4-37.6) 0.01 
Trim 3 29 50.9 (33.7-68.2) 0.0002 29 21.9 (13.2-30.6) 0.0056 
Parity 
Primiparous 53 39.5 (28-50.9) 
0.774 
53 13.3 (8.8-17.9) 
0.146 
Multiparous 43 37.0 (23.6-50.4) 43 19 (12.5-25.5) 
Ethnicity 
**** 
Caucasian 58 38 (28.1-48) 
0.864 
58 16.3 (12-20.5) 
0.997 
Other 37 39.6 (22.8-56.4) 37 16.3 (8.3-24.2) 
Mother’s 
age 
20-34 63 37.9 (27.3-48.4) 
0.9 
63 14.6 (10.1-19) 
0.27 
35-42 33 38.9 (23.2-54.5) 33 19.1 (11.2-26.9) 
Mode of 
Delivery ** 
Vaginal  45 38.2 (27-49.5) 
0.9 
45 16.4 (11.3-21.6) 
0.9 
C-Section 49 39.2 (24.8-53.6) 49 15.9 (9.4-22.3) 
Gestation 
35-39 weeks 35 33.7 (21.6-45.9) 
0.4 
35 19.1 (11.2-27.0) 
0.27 
≥40 weeks 61 41.2 (29.1-53.4) 61 14.6 (10.2-19.0) 
Maternal 
BMI *** 
<25 52 38.6 (25.5-51.8) 
0.93 
52 17.1 (11.3-22.8) 
0.56 
≥25 41 
17.1 (11.3-
22.8)36.6 (24.2-
48.5) 
41 
14.8 (9.6-19.9)13.2 
(9.1-17.2) 
*p values are results of unweighted t-test, for trimester of vaccination this is to the unvaccinated 
group. 
** Delivery mode not recorded for 2 donors 
*** BMI not recorded for 3 donors 
**** Ethnicity not recorded for 1 donor 
